Merrimack's lead cancer drug flunks first of three PhII tests
Merrimack Pharmaceuticals ($MACK) has nailed down the top-line results for one group of cancer patients in a mid-stage trial of Tarceva combined with its lead drug MM-121, partnered with Sanofi ($SNY). And it's not good.
Investigators say that the cohort of 50 patients suffering from non-small cell lung cancer patients in the single arm study failed to hit the primary endpoint of a 40% progression-free survival rate at four months. This particular cohort was made up of a group whose disease had "progressed on an anti-EGFR tyrosine kinase inhibitor." Two other cohorts--"patients with EGFR wild-type tumors who have recurring or progressive disease following at least one chemotherapy-containing regimen in the metastatic setting and who have had no prior EGFR-TKI therapy (Group A) and patients with a known EGFR-activating mutation who have had no prior EGFR-TKI therapy in the metastatic setting (Group B)"--are still being evaluated.
Read more: Merrimack's lead cancer drug flunks first of three PhII tests - FierceBiotech http://www.fiercebiotech.com/story/merrimacks-lead-lung-cancer-drug-flunks-first-three-phii-tests/2013-04-04#ixzz2PabU2kaG
Subscribe at Fierce Pharma
No comments:
Post a Comment